| ORIGINAL ARTICLE |
|
| Year : 2019 | Volume
: 2
| Issue : 1 | Page : 15-18 |
|
|
A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India
Anita C Ramesh1, Sagar B Bhagat2
1 Department of Medical Oncology, HCG Cancer Centre, Chennai, Tamil Nadu, India
2 Department of Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, Maharashtra, India
Correspondence Address:
Dr. Sagar B Bhagat
Glenmark Pharmaceuticals Limited, Mumbai 400099, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | 5 |
DOI: 10.4103/JCO.JCO_2_19
|
|
|
Background: Control of chemotherapy-induced nausea and vomiting is a crucial factor in ensuring patient’s compliance and adherence to cancer chemotherapy cycle. Fosaprepitant is a water-soluble N-phosphoryl derivative of aprepitant, which is often administered along with 5-hydroxytryptamine 3 antagonist and a steroid in patients with highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Materials and Methods: A single-centric, retrospective cohort study was conducted in HCG Cancer Centre in South India, where patients who were prescribed fosaprepitant as a part of standard therapy were enrolled. Results: Among the 290 patients who were included in the analysis, 41.72% were male, 58.27% were female, and 36.20% belonged to 51–60 years of age. Advanced breast carcinoma was the most common diagnosis in 38.96% patients. HEC was prescribed in 222 patients; moderate emetogenic drugs and regimen were prescribed in 62 patients. Among patients who were prescribed HEC and MEC drugs and regimen, fosaprepitant, palonosetron, and dexamethasone were prescribed on day 1 followed by dexamethasone on days 2, 3, and 4. No infusion site reaction, hiccups, or any other adverse reactions were noted. Complete response was noted in all patients (100%) with HEC and MEC regimen cases. The formulation was well tolerated with none reporting any persistent or delayed or breakthrough emesis. Conclusion: Single-dose fosaprepitant used in combination with palonosetron and dexamethasone was well tolerated and effective in preventing chemotherapy-induced vomiting in patients receiving highly and moderately emetogenic drugs and regimen. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
